The 10-second takeaway
For the quarter ended Dec. 31 (Q3), Forest Laboratories missed estimates on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly and GAAP earnings per share dropped to a loss.
Gross margins grew, operating margins dropped, net margins dropped.
Forest Laboratories chalked up revenue of $722.7 million. The 15 analysts polled by S&P Capital IQ expected revenue of $769.7 million on the same basis. GAAP reported sales were 40% lower than the prior-year quarter's $1.21 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.21. The 12 earnings estimates compiled by S&P Capital IQ anticipated -$0.05 per share. GAAP EPS were -$0.58 for Q3 versus $1.04 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 78.8%, 60 basis points better than the prior-year quarter. Operating margin was -25.5%, 5,500 basis points worse than the prior-year quarter. Net margin was -21.3%, 4,440 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $829.6 million. On the bottom line, the average EPS estimate is $0.18.
Next year's average estimate for revenue is $3.17 billion. The average EPS estimate is $0.54.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Forest Laboratories is hold, with an average price target of $37.26.
- Add Forest Laboratories to My Watchlist.